A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
Crossref DOI link: https://doi.org/10.1007/s00520-016-3429-2
Published Online: 2016-10-06
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Park, K. H.
Lee, S.
Park, J. H.
Kang, S. Y.
Kim, H. Y.
Park, I. H.
Park, Y. H.
Im, Y. H.
Lee, H. J.
Park, S.
Lee, S.I.
Jung, K.H.
Kim, Y.S.
Seo, Jae Hong
Funding for this research was provided by:
Dong-A ST
License valid from 2016-10-06